Pharma Nord Q10 used in the Q-symbio study
Pharma Nord Q10 does it again: Occupies the headlines in Health News Journals around the world. Most recently, Professor Svend Aage Mortensen from Rigshospitalet in Copenhagen and his colleagues in the EU and in Asia presented the results of the Q-symbio study at a congress for cardiologists in Lisbon, Portugal, 23 - 28 May 2013.
420 patients from nine different countries were included in the Q-symbio study that examined a group of persons with low levels of Q10.
Pharma Nord's Q10 dissolved in vegetable oil
The active treatment consisted of a soft gelatin capsule with 100 mg of Q10 three times a day for a period of two years. The purpose of the study was to find out how well those who got Q10 performed compared to those who had to do without.
Last year we saw another study with healthy elderly in the so-called KiSel-10 study where Dr. Urban Alehagen and his team of Swedish researchers used the same Pharma Nord Q10 formulation in combination with the selenium product SelenoPrecise – and with similar results.
Why Q10 from Pharma Nord?
Researchers prefer Pharma Nord Q10 because it is documented in more than 90 scientific studies and also has documentation for high bioavailability and safety. It is manufactured under Danish pharmaceutical control and is the official reference product for the ICQA (International Coenzyme Q10 Association).
In some countries, Pharma Nord also has Q10 registered as a medical drug.